At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ECT Pulse Amplitude and Medial Temporal Lobe Engagement
In Brief
A Phase 4 clinical trial evaluating MECTA Spectrum 5000Q Amplitude for Major Depressive Disorder. Completed, enrolled 62 participants across 1 site.
Detailed Summary
Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antidepressant effect of ECT, many patients experience transient memory impairment. This investigation will examine the impact of one ECT parameter (pulse amplitude or current) on brain changes (structure of connections within the brain) and clinical outcomes. The goal of this investigation is to determine the optimal parameter for an individual patient that will maintain the clinical response (reduce depression severity) and minimize side effects (eliminate memory issues related to treatment).
Study Details
Timeline
Interventions
Current